Navigation Links
Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100
Date:3/20/2012

NEWTON, Mass., March 20, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism. TREAT-NMD is a global network dedicated to expediting the delivery of promising new therapies to patients with neuromuscular disease. TACT provides independent, objective guidance on the therapeutic potential of drug candidates (novel or repurposed), which are submitted for review on a voluntary basis. In its review of HT-100, TACT found the drug candidate to be "ready for the clinic."

"TACT offers the opportunity for objective review of potential new therapies to help industry, researchers and patient advocacy groups. The review provides multi-disciplinary advice on the development of the potential therapies in the context of a realistic development pathway," said Volker Straub of TREAT-NMD. "TACT evaluated the proposal from Halo Therapeutics and felt it was well prepared, and that the compound has potential based on the proposed mechanism. Overall the plan to progress to a clinical trial is realistic."

DMD is a progressive and fatal neuromuscular disorder that afflicts approximately 1 in 3,500 boys worldwide.  HT-100, Halo's proprietary formulation of halofuginone, is an orally available small molecule drug candidate intended to reduce fibrosis and promote healthy muscle fiber regeneration. HT-100 works by inhibiting the pathological fibrotic process in muscle and directly stimulating healthy muscle fiber regeneration. The U.S. Food and Drug Administration recently granted orphan drug designation to HT-100. The company will begin a phase 2 study in the second half of 2012.

"We submitted HT-100 for a TACT review knowing that informed, objec
'/>"/>

SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics, Inc. Announces 2011 Financial Results
2. Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
3. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
4. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
5. ADHD Therapeutics Reviewed by NeuroPerspective
6. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
7. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
8. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
10. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
11. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline ... 2 diabetes therapeutic area. The Company is investigating ... worldwide. New Phase II data results for linagliptin ... the Company,s lead diabetes compound, were presented today at ...
... , Two-year study presented at the American Diabetes ... to standard insulin therapy in pulmonary function tests ... AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is ... in pulmonary function tests comparable to usual antidiabetic ...
Cached Medicine Technology:Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 2AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 3
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Teens who are sensitive ... likely to develop emotional symptoms such as anxiety and ... as these that may exacerbate issues teens experience after ... and in making decisions about when to return to ... these athletes," study authors Lisa Koehl and Dong Han, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Men who have a vasectomy ... a new study suggests. But the risk is ... involved with the study said more research is needed ... For the study, Harvard researchers analyzed data from ... 24 years, starting in 1986. During that time, 6,023 ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... Emergency Medical Service (EMS) responders felt better prepared to ... tactical training according to a new study in the ... the first study to specifically examine the EMS provider ... a shooter has not yet been neutralized or working ... such as the Columbine High School shooting, the Virginia ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Active shooter training increases comfort level of emergency responders 2
... associated with Alzheimer,s and mad cow disease, turns out ... paper published in Nature Chemical Biology , Frederic ... Universiteit Brussel describe that certain mutations of p53, an ... a way that the proteins start to aggregate. This ...
... 29 (HealthDay News) -- Dangerous methicillin-resistant staphylococcus aureus, or MRSA, ... this seasonal increase is more common in children than adults, ... analysis of MRSA cases that occurred at Rhode Island Hospital, ... children,s infections were higher in the third and fourth quarters ...
... application provided by the UK Resuscitation Council performed significantly ... did not, according to a study in the April ... approximately 30,000 people in the UK have an unexpected ... resuscitation research, survival rates for adults suffering a cardiac ...
... that liver transplant recipients who quit smoking have a ... keep smoking. In fact, SRMs were identified in 13.5% ... higher risk of malignancy in this study. Full findings ... Transplantation , a journal of the American Association for ...
... News) -- Death rates among teens and young adults aged 15 ... 4 years in many countries, says a new study that ... of researchers that analyzed the causes and patterns of death among ... 2004 also found that death rates among young males aged 15 ...
... Severely obese men and women who have bariatric surgery may ... much of their pre-surgery risk for experiencing disabling migraines, researchers ... a small study of obese patients with a history of ... roughly 66 pounds by the half-year point following either laparoscopic ...
Cached Medicine News:Health News:Cancer is a p53 protein aggregation disease 2Health News:MRSA Infections May Vary by Season 2Health News:Free phone app helped doctors perform better in simulated cardiac emergency 2Health News:Smoking in combination with immunosuppression poses greater risk for transplant-related carcinoma 2Health News:Death Rates of Children, Young Adults Show Reversal 2Health News:Weight-Loss Surgery May Cut Migraine Pain in Obese Patients 2Health News:Weight-Loss Surgery May Cut Migraine Pain in Obese Patients 3
... CC 527 is an assayed quality control material ... electrolyte, and CO-Oximeter instrumentation. It is for specific ... and hemoglobin fractions (280, 288, and 270) and ... 527 may also be used on the IRMA ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
For the qualitative detection of igG antibodies specific to Helicobacter pylori in human serum, plasma and whole blood specimens...
Medicine Products: